AC Immune to Provide Strategy and Pipeline Update During Jefferies Virtual London Healthcare Conference
To feature discussion of the Company’s world-leading therapeutic and diagnostic candidates targeting TDP-43
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in a fireside chat during the upcoming Jefferies Virtual London Healthcare Conference.